French health authorities launched the 2026 winter immunization campaign against respiratory syncytial virus on September 16, 2026, deploying dual prevention strategies to protect infants from severe bronchiolitis. The national rollout pairs maternal vaccination during pregnancy with direct monoclonal antibody injections for newborns, aiming to curb winter pediatric hospital admissions across regions like Bourgogne-Franche-Comté and the Lyon metropolis.
Every winter, bronchiolitis affects nearly 30 percent of infants in France, representing approximately 480,000 cases annually, according to data from the CHU Dijon Bourgogne. The condition remains the primary cause of hospital admission for acute respiratory infections among babies under two years old. To combat these high figures, the National Agency for the Safety of Medicine and Health Products, known as the ANSM, oversees the distribution of preventive treatments.
Maternal Vaccination and Infant Antibodies
The prevention effort relies on two distinct medical pathways. Pregnant women can receive the Abrysvo vaccine between the 32nd and 36th week of amenorrhea. Alternatively, newborns can receive a direct dose of a monoclonal antibody such as Beyfortus to provide passive protection without stimulating the infant’s immune system.
During a visit to the Dijon University Hospital on October 1, 2026, Mathilde Marmier, general director of the Regional Health Agency for Bourgogne-Franche-Comté, met with medical staff to review the deployment of both options. Official figures show that maternal vaccination coverage among eligible pregnant women in the region increased from just under 27 percent during the 2024-2025 season to more than 53 percent for the subsequent period.
Regional Disparities and Treatment Options
Not all infants face the same level of risk from the virus. Research published by the Hospices Civils de Lyon indicates that environmental and social determinants heavily influence severe infection rates. Dr. Jean-Sébastien Casalegno, a virologist at the HCL who directed the study, noted that severe cases cluster in specific areas, such as the southeastern communes of the Lyon metropolis, including Vénissieux. Factors such as socio-economic conditions, household overcrowding, and atmospheric pollution drive these disparities.
To address these varying risk levels, health agencies expanded available treatments. Alongside Beyfortus, which is approved for the first and second seasons of exposure, the treatment Enflonsia joined the available options for newborns during their first exposure season. Meanwhile, Synagis remains strictly reserved for infants born prematurely or those facing high medical risks, as reported by Expressions.
Avoiding Medication Errors and Overlaps
The ANSM issued updated pharmacovigilance data addressing potential medication errors regarding infants whose mothers received the Abrysvo vaccine during pregnancy. Health authorities clarified that if a mother was vaccinated sufficiently early, administering a monoclonal antibody to the newborn is generally unnecessary. However, exceptions apply for premature births or when delivery occurs less than 14 days after maternal vaccination, situations requiring direct evaluation by hospital care teams.
In addition to immunizations, health officials stress that basic hygiene measures remain vital throughout the epidemic period. Regular hand washing, ventilating living spaces, wearing masks when experiencing respiratory symptoms, and limiting contact with sick individuals protect infants regardless of whether they received medical prevention.
Frequently Asked Questions
Why is Beyfortus not considered a vaccine?
Beyfortus is a monoclonal antibody that provides passive protection by supplying ready-to-act antibodies directly to the infant, whereas a vaccine stimulates the baby’s own immune system to produce its own antibodies.
When should pregnant women receive the Abrysvo vaccine?
The vaccine is administered to expectant mothers between the 32nd and 36th week of amenorrhea to allow sufficient time for antibodies to transfer to the fetus before birth.
Which infants are eligible for Synagis?
Synagis is strictly reserved for infants who are born prematurely or who present a high risk for severe respiratory syncytial virus infections.
What environmental factors increase severe bronchiolitis risk?
Studies from the Hospices Civils de Lyon show that lower socio-economic status, housing overpopulation, local climate conditions, and atmospheric pollution contribute to higher rates of severe hospital admissions.
Worth a look